OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Submission Deadline: January 30, 2024 (Open) Submit Now
Ashwini Arjuna, MD
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA
Research Interests: Lung transplantation; Advanced pulmonary disease; Pulmonary hypertension; Antibody mediated rejection; COVID and lung transplant
About This Topic
From the era of early experimental lung transplant strategies to successful lung implantation for various advanced lung diseases with improved survival and quality of life, the science of surgical and medical management of lung transplantation has evolved significantly. The growing gap between a high demand and a limited supply of these valuable organs has made us expand the donor pool with strategies including Ex Vivo Lung Perfusion (EVLP), donation after cardiac death (DCD donation), Hepatitis C donor pool, innovative ventilator mechanisms to help salvage more organs to be viable for donation, to name a few. Despite this exponential growth, chronic rejection in the forms of restrictive allograft dysfunction, bronchiolitis obliterans syndrome, antibody mediated rejection , remains the most dreadful limiting factor for long term outcomes after transplantation thus prompting ongoing research and scientific work. The COVID pandemic has added another layer complexity further letting us push the boundaries of lung transplantation.
The Special Issue in Lung Transplantation will provide a platform for ongoing research, studies and investigations to come to the limelight from professionals involved in this niche area of interest.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (email@example.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Received: 08 June 2023; Published: 21 November 2023; doi: 10.21926/obm.transplant.2304202
Treatment options for end stage lung diseases are limited to stabilizing lung failure, decreasing disease progression, and symptom management, but significant reversal of lost lung function is often not possible. For well selected patients, lung transplantation may be a viable option to improve both longevity and quality of life. Though outcom [...]